(E)-1-(3,5-Dimethoxystyryl)-2,4-dimethoxybenzene; 2,4,3',5'-tetramethoxystilbene; (E)-2,3',4,5'-tetramethoxystilbene; CHEMBL46909; 1-[(E)-2-(2,4-dimethoxyphenyl)ethenyl]-3,5-dimethoxybenzene; Benzene, 1-[(1E)-2-(3,5-dimethoxyphenyl)ethenyl]-2,4-dimethoxy-; SR-01000597603; Cytochrome P450 1B1 Inhibitor, TMS; 3,5,2',4'-tetramethoxy-trans-stilbene; Oxyresveratrol tetramethyl ether; SCHEMBL4366766; 1-[2,(3,5-Dimethoxyphenyl)ethenyl]-2,4-dimethoxybenzene; HMS3412F17; HMS3648A21; HMS3676F17; BCP21292; EX-A1015; ZINC3875137; 1747AB; BDBM50108052; MFCD03428621; AKOS015967529; CS-5626; VZ20197; Trans-2,3',4,5'-tetramethoxystilbene; trans-2,4,3',5'-tetramethoxystilbene; AS-71536; HY-19340; trans-2,4,3'',5''-tetramethoxystilbene; B6768; 1-(3,5-Dimethoxystyryl)-2,4-dimethoxybenzene; S-7732; 144T921; 2,4,3',5'-tetramethoxystilbene, >=98% (HPLC); J-015362; SR-01000597603-1; SR-01000597603-2; BRD-K45988865-001-01-0; (E)-4,5'-(ethene-1,2-diyl)bis(1,3-dimethoxybenzene); (E)?-?1-?(3,?5-?Dimethoxystyryl)?-?2,?4-?dimethoxybenzene; 1-[(E)-2-(3,5-dimethoxyphenyl)vinyl]-2,4-dimethoxybenzene; 1-[(1E)-2-(3,5-dimethoxyphenyl)ethenyl]-2,4-dimethoxybenzene; Benzene,1-[(1E)-2-(3,5-dimethoxyphenyl)ethenyl]-2,4-dimethoxy-